Misplaced Pages

MINE (chemotherapy)

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from MINE-R) Medical treatment for lymphoma

MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.

Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.

The -MINE regimen consists of:

  1. Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  2. Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  3. Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  4. Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
  5. Etoposide - a topoisomerase inhibitor.

Dosing regimen

Drug Dose Mode Days
Rituximab 375 mg/m IV infusion Day 1
Mesna 1330 mg/m IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide Days 1-3
Ifosfamide 1330 mg/m IV infusion over 1h Days 1-3
Mitoxantrone 8 mg/m IV infusion Day 1
Etoposide 65 mg/m IV infusion over 1h Days 1-3

References

  1. A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas
  2. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Category: